Plant-based diet tied to improved sexual health during prostate cancer treatment

Nubeqa + androgen deprivation therapy improves rPFS for mHSPC in phase III trial

The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, research suggests, which could contribute to higher rates of aggressive prostate cancer in African American men.

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.

Cancer cells salvage purine nucleotides—including dietary purines—to fuel tumor growth

Cancer cells salvage purine nucleotides to fuel tumor growth, including purines in foods we eat, an important discovery with implications for cancer therapies from research by Children’s Medical Center Research Institute at UT Southwestern published in Cell.